EGFR and non-small cell lung carcinoma: More recently, the 3rd generation of EFGR TKI (e.g. osimertinib), effective for NSCLC patients with the EGFR T790M mutation has achieved strong and durable responses, as demonstrated in the phase 2 AURA2 trial [10].